How CROs can market therapeutic area expertise as a key differentiator

Key takeaways

• Sponsors pick CROs that can show they have already handled the specific problems in an indication, not ones that list general trial capabilities.
• Protocol amendments now hit 76% of protocols, so proof that your team designs studies that hold up is a strong selling point.
• White papers, design case discussions and regulatory commentary turn scientific knowledge into content sponsors read.
• LinkedIn, DIA and specialty conferences, focused newsletters and search-ready therapeutic area pages reach biopharma decision-makers.
• Measure success by RFP sources and lead quality, not raw traffic.

Therapeutic area expertise is the reason a sponsor shortlists one CRO over another when timelines and budgets look alike. When pharmaceutical and biotech teams compare RFP responses, they look for evidence that a CRO has run studies like theirs before and knows where those studies tend to go wrong. This guide from Emulent explains how CROs can turn that experience into marketing that sponsors find, read and trust.

Why do sponsors weigh therapeutic depth so heavily when choosing a CRO?

Sponsors weigh therapeutic depth because mistakes in an unfamiliar indication cost months and money. A weak protocol, the wrong sites or slow enrollment in a rare disease can push a program far off schedule.

The data backs up that worry. A 2024 Tufts CSDD study in Therapeutic Innovation & Regulatory Science found that the share of protocols with at least one amendment rose from 57% to 76% since 2015, and the average number of amendments per protocol climbed to 3.3. Earlier Tufts CSDD research put the median direct cost of a substantial amendment at $141,000 for Phase II and $535,000 for Phase III. A CRO that can show it designs studies that avoid those changes has a strong story to tell.

Sponsors usually judge four things when they review CRO qualifications:

• Familiarity with protocol design in the indication, including endpoint selection and design trade-offs specific to the disease.
• Site network strength, meaning working relationships with principal investigators and specialized sites that enroll on time.
• Regulatory experience in the category, such as past FDA interactions for similar programs, which sponsors cannot wait for a vendor to learn mid-trial.
• Knowledge of the patient population, especially for rare disease and CNS studies where recruiting and keeping patients takes skill.

Sponsors are not hiring a CRO that can run any trial. They want one that has already seen the problems their program is likely to face, and your marketing should prove that.

How can CROs turn scientific expertise into content sponsors actually read?

CROs turn expertise into readable content by publishing specific, indication-level thinking instead of capability lists. Slide decks and past-study tables still have a place, but they rarely give a sponsor enough confidence to add you to an RFP list.

Content formats that show therapeutic area authority include:

• Indication-specific white papers on topics such as rare disease enrollment, CNS endpoint selection or oncology biomarker strategy.
• Protocol design case discussions that walk through the kinds of design decisions your team faced in an area and the reasoning behind them, without sharing confidential sponsor data.
• Regulatory commentary that breaks down new FDA or ICH guidance for sponsors in your focus areas. The final ICH E6(R3) Good Clinical Practice guideline, adopted in January 2025, is a good example of a change sponsors want explained.
• Disease area explainers that cover the clinical development realities of an indication and signal you know the science and the patients.

The aim is to build familiarity over time, so your name is already trusted when a sponsor is ready to issue an RFP.

Which channels reach pharmaceutical and biotech decision-makers?

The channels that reach biopharma buyers are the places they go for peer-level expertise, not broad B2B ad networks. A focused mix works better than spreading budget thin.

• LinkedIn is the main professional platform for clinical and drug development staff. Posts from your senior scientists, in-depth articles and targeted paid campaigns by job title and company reach the right people.
• Conferences such as the DIA Global Annual Meeting, ACRP and specialty society meetings put your team in front of sponsors. Speaking on a clinical development topic earns more trust than a booth alone.
• An email newsletter on your therapeutic specialty keeps you in front of sponsors between RFPs, as long as it offers useful insight rather than announcements.
• Search-ready website content earns its place because sponsors research CROs before they reach out. Pages built around indication keywords and development problems get found.
• Direct outreach from a therapeutic area expert, tied to a shared publication or conference session, lands better than a generic business development email.

Decision-makers tend to trust scientific conversations and published work more than polished sales material, so put your scientists in front of the audience wherever you can.

How do you build a content program around your therapeutic focus areas?

You build a content program by publishing in three layers and publishing on a regular schedule for at least a year. One or two articles will not set you apart, because sponsors judge your whole body of work.

• The awareness layer includes short posts, LinkedIn updates from scientific staff and brief explainers that reach people before they start a CRO search.
• The authority layer includes white papers, regulatory analysis, published research and detailed case studies that serious evaluators read while comparing vendors.
• The buyer layer includes capability summaries by indication, team credentials and proof points that reassure a sponsor close to a decision.

Frequency counts as much as quality. A CRO that publishes two to four solid pieces a month for a year leaves a much stronger impression than one that posts a burst of content and then goes quiet. Review what you have in each layer and fill the gaps first.

What does your website need to support therapeutic area positioning?

Your website needs to be organized by indication, because that is how sponsors search. Many CRO sites explain what a CRO does in general, which sponsors already know.

• Give each focus area its own page covering your team’s experience, the study types you run, regulatory points and examples of clinical problems you have solved.
• Show your scientific staff’s academic backgrounds, publications and conference talks so sponsors can see who would work on their program.
• Share study experience numbers where you can, such as studies completed in an indication, patient populations enrolled and countries in your site network.
• Describe services in the language sponsors use for their indication, which also helps search engines match your pages to their queries.

How do you know whether your therapeutic area marketing is working?

You know it is working when RFP volume and lead quality improve, not when traffic alone rises. For CROs, the signals worth tracking connect directly to new business.

• Track the source of every RFP, whether a white paper, a search visit or a conference talk came first.
• Watch time on page and scroll depth on therapeutic area pages to confirm the right audience is reading them.
• Review download rates and contact quality on gated white papers and guides.
• Count speaking and trade publication invitations as a sign your team is becoming a recognized voice.
• Check whether inbound leads increasingly come from sponsors already working in your focus areas.

One caveat: long sales cycles in clinical services mean results build slowly. Expect six to twelve months before content shows up clearly in RFP sources, and avoid judging the program on a single quarter.

How can CROs build a marketing program that reflects the expertise they already have?

CROs win more of the right RFPs by making their expertise clear, specific and credible long before a bid goes out. That takes a planned program rather than occasional posts.

Emulent helps CROs turn scientific experience into content and websites that sponsors trust and find when they need them. If you want help shaping your CRO marketing strategy, contact the Emulent team to talk through your therapeutic focus areas.